Review: taking Requip xl and Memantine hydrochloride together


Summary

Drug interactions are reported among people who take Requip xl and Memantine hydrochloride together. This review analyzes the effectiveness and drug interactions between Requip xl and Memantine hydrochloride. It is created by eHealthMe based on reports of 151 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Requip Xl

Requip xl has active ingredients of ropinirole hydrochloride. It is often used in parkinson's disease. (latest outcomes from Requip xl 954 users)

Memantine Hydrochloride

Memantine hydrochloride has active ingredients of memantine hydrochloride. It is often used in dementia alzheimer's type. (latest outcomes from Memantine hydrochloride 911 users)

On Sep, 21, 2016

151 people who take Requip Xl, Memantine Hydrochloride are studied.


Number of reports submitted per year:

Requip xl and Memantine hydrochloride drug interactions.

Drug effectiveness over time:

Requip Xl:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Memantine Hydrochloride:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Requip Xl:
  • female: 100.0% - (1 of 1 people)
  • male: 40.0% - (2 of 5 people)
Memantine Hydrochloride:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 4 people)

Drug effectiveness by age:

Requip Xl:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 50.0% - (2 of 4 people)
Memantine Hydrochloride:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 3 people)

Most common drug interactions over time *:

< 1 month:
  • death
  • perirectal abscess
  • loss of consciousness
  • confusional state
  • abnormal dreams
  • aggression
  • agitation
  • amnesia
  • dizziness
  • fall
1 - 6 months:
  • death
  • cluster headache
  • lip swelling
  • perirectal abscess
  • amnesia
  • asthenia
  • constipation
  • decubitus ulcer
  • dizziness
  • dysphagia
6 - 12 months:
  • abnormal dreams
  • cluster headache
  • confusional state
  • hallucination
  • micturition urgency
1 - 2 years:
  • rash generalised
5 - 10 years:
  • abnormal dreams
  • confusional state
  • hallucination
  • micturition urgency
10+ years:
  • diarrhoea
  • drug ineffective
  • fall
  • gait disturbance
  • hallucination
not specified:
  • asthenia
  • death
  • drug ineffective
  • fall
  • confusional state
  • weight decreased
  • dizziness
  • weight increased
  • cognitive disorder
  • hallucination

Most common drug interactions by gender *:

female:
  • asthenia
  • fall
  • dizziness
  • drug ineffective
  • malaise
  • hypotension
  • abasia
  • adverse event
  • apathy
  • aphasia
male:
  • death
  • confusional state
  • hallucination
  • drug ineffective
  • weight decreased
  • weight increased
  • cognitive disorder
  • perirectal abscess
  • fall
  • failure to thrive

Most common drug interactions by age *:

30-39:
  • apraxia
  • convulsion
  • drug effect decreased
  • muscle spasms
  • weight increased
  • cognitive disorder
  • coordination abnormal
40-49:
  • death
  • adverse reaction
  • asthenopia
  • bronchitis
  • depressed mood
  • feeling cold
  • hypoaesthesia oral
  • peripheral coldness
  • pneumonia
  • sinusitis
50-59:
  • multiple sclerosis relapse
  • weight decreased
  • dizziness
  • drug ineffective
  • feeling hot
  • flushing
  • nasopharyngitis
  • ankylosing spondylitis
  • balance disorder
  • confusional state
60+:
  • death
  • asthenia
  • fall
  • confusional state
  • hallucination
  • drug ineffective
  • perirectal abscess
  • tremor
  • failure to thrive
  • laceration

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Requip xl and Memantine hydrochloride?


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.